Quotes 5-day view Delayed Nasdaq
03/01/2021
03/02/2021
03/03/2021
03/04/2021
03/05/2021
Date
152.14(c)
154.63(c)
143.7(c)
133.15(c)
135.27(c)
Last
671 111
1 123 237
1 327 452
1 739 146
2 163 895
Volume
+3.37%
+1.64%
-7.07%
-7.34%
+1.59%
Change
Sales 2021
369 M
-
-
Net income 2021
-309 M
-
-
Net cash position 2021
972 M
-
-
P/E ratio 2021
-47,8x
Yield 2021
-
Sales 2022
508 M
-
-
Net income 2022
-279 M
-
-
Net cash position 2022
828 M
-
-
P/E ratio 2022
-50,6x
Yield 2022
-
Capitalization
13 585 M
13 585 M
-
EV / Sales 2021
34,2x
EV / Sales 2022
25,1x
Nbr of Employees
864
Free-Float
93,8%
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and...
Notations Surperformance© of Guardant Health, Inc.
Trading Rating :
Investor Rating :
All news about GUARDANT HEALTH, INC.
News in other languages on GUARDANT HEALTH, INC.
Analyst Recommendations on GUARDANT HEALTH, INC.
Chart GUARDANT HEALTH, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends GUARDANT HEALTH, INC.
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
12
Average target price
170,45 $
Last Close Price
135,27 $
Spread / Highest target
44,2%
Spread / Average Target
26,0%
Spread / Lowest Target
-38,6%
Please enable JavaScript in your browser's settings to use dynamic charts.